Hyderabad: Biotechnology company Ocugen will commercialise Bharat Biotech’s Covaxin in Mexico. The two companies amended their present co-development, supply and commercialisation agreement on Bharat Biotech’s Covid-19 vaccine Covaxin to include Mexico. With this amendment, Ocugen now has commercialisation rights of Covaxin for all of North America. “We’re excited to commercialise Covaxin in Mexico, as authorities […]
Ocugen, the US partner of Bharat Biotech, has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to evaluate the Covid-19 vaccine candidate, BBV152, known as Covaxin outside the United States. The phase 3 trial proposed in the IND is designed to establish whether the immune response experienced by […]
Ocugen said Bharat Biotech completed and posted its phase 3 clinical trial results for Covaxin demonstrating 77.8 per cent efficacy against overall Covid-19 disease
With herd immunity and a significant percentage of the US population vaccinated, the pandemic is reducing, and keeping this in view, the USFDA communicated that no new emergency use authorization would be approved for new Covid-19 vaccines
US-based Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to Bharat Biotech, in addition to sharing the profit from sales of Covaxin in Canada
Under the terms of the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including emergency use authorisation (EUA)) and commercialisation for the US market.
